IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Comprehensive Review of Maribavir: Pharmacology, Clinical Efficacy, Safety, and Future Directions

Radhika Katpale, Sagar Tambe, Anamika Kakad, Aishwarya Jadhav.

Samarth Institute of Pharmacy, Belhe, Pune-412410, Maharashtra India.

Corresponding Author-

Name- Radhika Katpale

Address- Samarth Institute of Pharmacy, Belhe, Pune-412410, Maharashtra India.

ABSTRACT

Human cytomegalovirus (CMV) remains one of the most clinically significant opportunistic viral pathogens affecting immunocompromised populations, particularly hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. Despite advances in antiviral pharmacotherapy, CMV infection continues to impose substantial morbidity and mortality due to limitations associated with conventional treatments, including toxicity, resistance, and pharmacokinetic challenges.

Maribavir, a benzimidazole riboside antiviral agent, represents a paradigm shift in CMV therapeutics due to its unique mechanism of action targeting the UL97 protein kinase rather than the viral DNA polymerase. This distinction confers several clinical advantages, including reduced hematologic and renal toxicity and efficacy against strains resistant to conventional antivirals.

This comprehensive review critically evaluates maribavir across multiple dimensions: molecular pharmacology, pharmacokinetics, clinical efficacy, safety, resistance mechanisms, and future therapeutic potential. Particular emphasis is placed on its role in refractory and resistant CMV infections, comparative effectiveness against existing therapies, and its integration into evolving antiviral treatment paradigms.

Emerging challenges including resistance mutations, recurrence rates, and drug–drug interactions are examined in detail, alongside future research directions such as combination therapy, precision medicine approaches, and expanded indications in pediatric and prophylactic settings.



Keywords: Maribavir, CMV, Pharmacology of Maribavir, Clinical Efficacy of Maribavir.

Introductions:

Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in immunocompromised populations, particularly in hematopoietic stem cell and solid organ transplant recipients. As a member of the herpesvirus family, CMV establishes lifelong latency following primary infection, with the potential for reactivation under conditions of impaired immunity. Despite the availability of established antiviral therapies such as Ganciclovir and Foscarnet, clinical management is often complicated by drug-related toxicities, limited efficacy in resistant strains, and the need for prolonged intravenous administration. These challenges have highlighted the urgent need for novel therapeutic agents with improved safety profiles and distinct mechanisms of action.[1]

In this context, Maribavir has emerged as a first-in-class antiviral that targets the CMV UL97 protein kinase, representing a paradigm shift in antiviral drug development. Unlike traditional DNA polymerase inhibitors, maribavir interferes with key regulatory processes in the viral life cycle, including DNA replication and nuclear egress, thereby offering a targeted and efficient approach to viral suppression. Clinical studies have demonstrated its efficacy in treating refractory and resistant CMV infections, along with a favorable safety profile that minimizes hematologic and renal toxicity. This review aims to provide a comprehensive analysis of maribavir, encompassing its pharmacology, clinical efficacy, safety, resistance mechanisms, and future therapeutic potential in the evolving landscape of CMV management. [2]

Clinical Significance of Cytomegalovirus:

Human cytomegalovirus (CMV), a member of the β-herpesvirus subfamily, is a ubiquitous pathogen infecting a large proportion of the global population. While typically asymptomatic in immunocompetent individuals, CMV poses a serious threat in immunocompromised patients, including:

- Hematopoietic stem cell transplant (HSCT) recipients
- Solid organ transplant (SOT) recipients
- Patients with advanced HIV/AIDS
- Individuals undergoing immunosuppressive therapy

CMV infection in these populations can lead to:

- CMV disease (e.g., pneumonitis, colitis, retinitis)
- Graft rejection or failure
- Secondary opportunistic infections
- Increased mortality

The clinical burden of CMV is compounded by its ability to establish lifelong latency and reactivate under conditions of immune suppression. [3]

Limitations of Conventional CMV Therapies:

Historically, CMV management has relied on antivirals targeting viral DNA polymerase, including:

- Ganciclovir / valganciclovir
- Foscarnet
- Cidofovir

While effective, these therapies are associated with significant drawbacks:

Toxicity

- Ganciclovir: severe neutropenia and bone marrow suppression
- Foscarnet: nephrotoxicity and electrolyte imbalance
- Cidofovir: dose-limiting renal toxicity

Resistance

- UL97 mutations → ganciclovir resistance
- UL54 mutations → cross-resistance among polymerase inhibitors

Administration Challenges

- Intravenous delivery for foscarnet and cidofovir
- Frequent monitoring requirements

Clinical Gaps

- Limited options for refractory CMV
- Poor tolerability in long-term use

These limitations have driven the need for novel antivirals with improved safety and unique mechanisms of action. [4]

Emergence of Maribavir:

Maribavir represents a first-in-class antiviral targeting the CMV UL97 protein kinase. Its development marks a shift away from DNA polymerase inhibition toward targeting viral regulatory pathways.

Key advantages include:

- Oral administration
- Reduced hematologic and renal toxicity
- Activity against resistant CMV strains

Maribavir has gained regulatory approval for treatment of refractory or resistant CMV infection in transplant recipients, positioning it as a critical addition to the antiviral arsenal. [5]

Biology and Pathogenesis of Cytomegalovirus:

Human cytomegalovirus (CMV) is a large, enveloped, double-stranded DNA virus belonging to the β-herpesvirus subfamily, characterized by its complex genomic structure and ability to establish lifelong persistence within the host. The viral genome, approximately 235 kilobases in size, encodes a wide array of structural, regulatory, and enzymatic proteins that facilitate viral replication, immune evasion, and latency. Structurally, CMV consists of an icosahedral capsid surrounded by a tegument layer containing viral proteins essential for early infection, all enclosed within a lipid envelope studded with glycoproteins that mediate host cell entry. Infection begins when viral envelope glycoproteins interact with host cell receptors, enabling membrane fusion and delivery of the viral capsid into the cytoplasm, followed by transport to the nucleus where replication occurs. [6]

The CMV replication cycle is temporally regulated and proceeds through immediate-early (IE), early (E), and late (L) phases of gene expression. During the immediate-early phase, viral proteins initiate transcriptional activation and modulate host cellular machinery to create a permissive environment for replication. This is followed by the early phase, during which proteins involved in viral DNA synthesis are produced, including enzymes necessary for genome replication. The late phase is characterized by the synthesis of structural proteins required for virion assembly. Newly formed viral DNA is packaged into capsids within the nucleus, and mature virions are subsequently transported to the cytoplasm through a process involving disruption of the nuclear lamina. The viral UL97 protein kinase plays a critical role in this process by phosphorylating both viral and host proteins, thereby facilitating nuclear egress and efficient virion maturation.

A defining feature of CMV biology is its ability to establish latency after primary infection. Latency is primarily maintained in hematopoietic progenitor cells and cells of the myeloid lineage, where the viral genome persists in a transcriptionally silent or minimally active state without producing infectious virions. This latent reservoir enables the virus to evade immune detection and persist for the lifetime of the host. Reactivation of CMV can occur when host immune surveillance is compromised, such as during immunosuppressive therapy, transplantation, or advanced HIV infection. Reactivation involves the re-initiation of viral gene expression, leading to productive replication and dissemination throughout the host. [7]

CMV pathogenesis is closely linked to both direct viral cytopathic effects and indirect immunomodulatory mechanisms. Direct effects include cellular damage resulting from viral replication, leading to tissue-specific manifestations such as pneumonitis, colitis, hepatitis, and retinitis. Indirect effects arise from CMV-mediated immune dysregulation, including the suppression of T-cell responses, alteration of cytokine signaling, and enhancement of inflammatory pathways. These immunological alterations not only facilitate viral persistence but also predispose individuals to secondary infections and graft rejection in transplant recipients. Furthermore, CMV encodes multiple immune evasion proteins that interfere with antigen presentation, natural killer (NK) cell recognition, and interferon responses, thereby allowing the virus to replicate despite host immune defenses. [8]

The central role of the UL97 kinase in CMV replication and pathogenesis has made it a critical target for antiviral drug development. UL97 is involved in multiple stages of the viral life cycle, including phosphorylation of viral proteins required for DNA replication and modification of host cell structures to enable viral egress. Its essential function and virus-specific nature provide a strategic advantage for targeted therapy, as inhibition of UL97 can disrupt viral replication without significantly affecting host cellular processes. This mechanistic insight underpins the development of maribavir, which selectively inhibits UL97 activity and thereby interferes with CMV replication at multiple stages.

Historical Evolution of CMV Antiviral Therapy:

The evolution of antiviral therapy for cytomegalovirus (CMV) has progressed through multiple generations, each defined by advances in molecular targeting, clinical efficacy, and safety profiles. The first generation of CMV antivirals was dominated by nucleoside and nucleotide analogs, most notably Ganciclovir, Foscarnet, and Cidofovir. These agents primarily target the viral DNA polymerase enzyme, thereby inhibiting viral DNA synthesis and replication. Ganciclovir, a guanine analog, requires phosphorylation by the viral UL97 kinase for activation, making it highly effective but also vulnerable to resistance arising from UL97 mutations. While it became the cornerstone of CMV therapy, particularly in transplant recipients, its clinical utility has been limited by significant myelosuppression, especially neutropenia. Foscarnet, a pyrophosphate analog, directly inhibits DNA polymerase without requiring activation, making it effective against ganciclovir-resistant strains; however, its use is constrained by dose-limiting nephrotoxicity and electrolyte disturbances. Similarly, cidofovir offers prolonged intracellular activity due to its long half-life but is associated with severe renal toxicity, necessitating careful monitoring and limiting its widespread use. Collectively, first-generation antivirals established the foundation of CMV management but highlighted critical challenges related to toxicity, resistance, and administration burden. [9]

Table 1: Comparison of CMV Antiviral Agents

Feature	Maribavir	Ganciclovir	Foscarnet	Cidofovir	Letermovir
Mechanism	UL97 kinase inhibitor	DNA polymerase inhibitor	DNA polymerase inhibitor	DNA polymerase inhibitor	Terminase inhibitor

Route	Oral	IV/Oral (prodrug)	IV	IV	Oral/IV
Use	Treatment (resistant CMV)	First-line treatment	Salvage therapy	Salvage therapy	Prophylaxis
Myelosuppression	Low	High	Low	Low	Minimal
Nephrotoxicity	Low	Low	High	High	Minimal
Resistance	UL97 mutation	UL97/UL54	UL54	UL54	UL56
Key Advantage	Low toxicity, oral	Established efficacy	No activation needed	Long half-life	Prophylaxis efficacy

The second generation of CMV antiviral therapy focused on improving pharmacokinetics, tolerability, and prophylactic efficacy while retaining DNA polymerase as the primary target. A key advancement in this generation was the development of oral prodrugs such as Valganciclovir, which significantly improved bioavailability compared to intravenous ganciclovir, enabling outpatient management and long-term prophylaxis. Despite these improvements, valganciclovir retained the same toxicity profile, particularly bone marrow suppression, as its parent compound. A more significant mechanistic breakthrough within this generation was the introduction of Letermovir, which targets the viral terminase complex rather than DNA polymerase. This novel mechanism inhibits viral DNA processing and packaging, offering a safer alternative with minimal hematologic or renal toxicity. Letermovir demonstrated substantial efficacy in CMV prophylaxis, particularly in hematopoietic stem cell transplant recipients, and marked a shift toward targeting non-polymerase viral functions. However, its role in the treatment of active CMV infection remains limited, as its antiviral potency in established disease is less robust compared to polymerase inhibitors. [10]

The third generation of CMV antivirals represents a paradigm shift toward highly specific viral targets with improved safety and resistance profiles, exemplified by Maribavir. Unlike earlier agents, maribavir selectively inhibits the UL97 protein kinase, a multifunctional enzyme critical for viral DNA replication, capsid assembly, and nuclear egress. This mechanism bypasses the need for activation by viral enzymes and avoids direct interaction with DNA polymerase, thereby reducing cross-resistance with traditional antivirals. Clinically, maribavir has demonstrated significant efficacy in patients with refractory or resistant CMV infections, particularly in transplant populations where treatment options are limited. Its oral administration and favorable safety profile—characterized by minimal myelosuppression and reduced nephrotoxicity—address many of the shortcomings of earlier therapies. However, challenges remain, including the potential for resistance through UL97 mutations and limited efficacy in prophylactic settings. Nonetheless, maribavir signifies a new era in CMV therapeutics, emphasizing targeted inhibition of viral regulatory pathways and paving the way for future antiviral innovations. [11]

Discovery and Development of Maribavir:

Chemical Class and Structure:

Maribavir is chemically classified as a benzimidazole riboside derivative, representing a structurally distinct class of antiviral agents compared to traditional nucleoside and nucleotide analogs. The theoretical basis of its design lies in the modification of the benzimidazole core to mimic riboside-like properties while avoiding incorporation into viral DNA. This structural configuration allows maribavir to selectively interact with viral enzymatic targets, particularly the UL97 protein kinase, without affecting host cellular DNA polymerases. Unlike classical antivirals such as Ganciclovir, which require phosphorylation for activation and function as chain terminators during DNA synthesis, maribavir's structure enables direct pharmacological activity without metabolic activation. Its molecular architecture enhances lipophilicity and membrane permeability, facilitating efficient oral absorption and intracellular access. The specificity of its chemical structure contributes to reduced off-target effects and improved tolerability, making it a strong candidate for targeted antiviral therapy. [12]

Preclinical Development:

The preclinical development of maribavir was grounded in theoretical pharmacological principles aimed at identifying selective inhibitors of viral kinases essential for cytomegalovirus (CMV) replication. Initial in vitro studies demonstrated that maribavir exhibits potent antiviral activity against CMV by inhibiting viral replication in infected cell cultures, including strains resistant to conventional DNA polymerase inhibitors. Theoretical models of enzyme inhibition suggested that maribavir acts through ATP-competitive binding at the UL97 kinase active site, thereby disrupting phosphorylation-dependent processes necessary for viral replication. In vivo studies in animal models further supported its pharmacological profile, revealing favorable oral bioavailability, dose-dependent antiviral efficacy, and minimal systemic toxicity. Importantly, preclinical toxicology assessments indicated a wide therapeutic index, with limited effects on host cellular processes due to its high specificity for viral targets. These findings aligned with the theoretical expectation that selective viral kinase inhibition would reduce the adverse effects commonly associated with less specific antiviral agents. Consequently, the preclinical data provided a robust foundation for advancing maribavir into clinical trials. [13]

Mechanistic Breakthrough:

The development of maribavir represents a theoretical and practical breakthrough in antiviral drug design, as it shifts the therapeutic paradigm from inhibition of viral DNA synthesis to targeted disruption of viral regulatory mechanisms. By selectively inhibiting the UL97 protein kinase, maribavir interferes with multiple stages of the CMV life cycle, including viral DNA replication, capsid assembly, and nuclear egress. From a mechanistic standpoint, this approach is significant because it targets a multifunctional enzyme that integrates several critical steps in viral propagation, thereby amplifying the antiviral effect. Theoretically, this multi-level inhibition reduces the likelihood of complete viral escape compared to single-target strategies. Furthermore, because UL97 is virus-specific and has limited homology with host kinases, maribavir achieves a high degree of selectivity, minimizing toxicity. This mechanism also circumvents the need for intracellular activation and avoids

cross-resistance with DNA polymerase inhibitors, addressing two major limitations of earlier antiviral therapies. Thus, maribavir exemplifies a next-generation antiviral strategy based on precise molecular targeting, offering both enhanced efficacy and improved safety in the treatment of CMV infections. [14]

Molecular Pharmacology of Maribavir:

Mechanism of Action:

Maribavir exerts its antiviral activity through selective inhibition of the cytomegalovirus (CMV) UL97 protein kinase, a viral enzyme that plays a central role in multiple stages of the viral life cycle. Theoretically, maribavir functions as an ATP-competitive inhibitor, binding to the active site of UL97 and preventing the phosphorylation of viral and host substrates required for efficient viral replication. Unlike conventional antivirals such as Ganciclovir, which depend on UL97-mediated phosphorylation for activation, maribavir directly inhibits the enzyme itself, thereby blocking its catalytic activity. This results in disruption of downstream processes, including viral DNA synthesis and nuclear egress. The uniqueness of this mechanism lies in its upstream targeting of viral regulatory pathways rather than direct interference with DNA polymerase, representing a significant shift in antiviral pharmacology. [15]



Effects on Viral Replication:

The inhibition of UL97 kinase by maribavir has profound effects on CMV replication at multiple stages. Theoretically, UL97 is essential for the phosphorylation of proteins involved in viral DNA replication, and its inhibition leads to impaired synthesis of viral genomes. Additionally, UL97 facilitates the reorganization of the nuclear lamina, a critical step required for the خروج (egress) of newly formed viral capsids from the nucleus to the cytoplasm. By blocking this process, maribavir effectively prevents the maturation and release of infectious virions. Furthermore, interference with

capsid assembly and protein trafficking contributes to a cumulative antiviral effect. This multi-step disruption enhances overall efficacy, as viral replication is hindered at several critical checkpoints rather than a single enzymatic step. [16]

Selectivity and Specificity:

A key theoretical advantage of maribavir lies in its high selectivity for the viral UL97 kinase over host cellular kinases. Structural differences between viral and host enzymes allow maribavir to preferentially bind to UL97, minimizing off-target interactions. This specificity is crucial in reducing toxicity, particularly when compared to DNA polymerase inhibitors that may affect host cell replication processes. The selective targeting of a virus-specific enzyme ensures that normal cellular functions remain largely unaffected, contributing to an improved safety profile. Moreover, this specificity reduces the likelihood of systemic adverse effects, making maribavir suitable for prolonged use in vulnerable patient populations such as transplant recipients. [17]

Pharmacodynamic Properties:

From a pharmacodynamic perspective, maribavir demonstrates concentration-dependent antiviral activity, with increasing drug concentrations leading to greater inhibition of viral replication. Theoretically, this relationship supports dose optimization strategies aimed at achieving maximal viral suppression while minimizing toxicity. Maribavir is associated with a rapid decline in CMV viral load following initiation of therapy, reflecting its potent inhibitory action on UL97-mediated processes. Sustained drug exposure maintains suppression of viral replication, although rebound viremia may occur in some cases upon discontinuation. The pharmacodynamic profile also suggests a relatively low threshold for effective antiviral activity, enabling consistent therapeutic outcomes across different patient populations. Additionally, its mechanism does not rely on viral replication rate alone, allowing activity even in partially latent or slowly replicating infections. [18]

Resistance at Molecular Level:

Resistance to maribavir arises primarily through mutations in the UL97 gene that alter the structure of the kinase and reduce drug binding affinity. Theoretically, these mutations occur within or near the ATP-binding domain or substrate recognition regions, leading to decreased inhibitory effectiveness. Unlike resistance to ganciclovir, which often involves impaired phosphorylation of the drug, maribavir resistance directly affects the drug–target interaction. Certain UL97 mutations may confer high-level resistance, potentially compromising clinical efficacy. However, due to its distinct mechanism, maribavir generally retains activity against CMV strains resistant to DNA polymerase inhibitors, highlighting its value in refractory infections. The emergence of resistance underscores the importance of antiviral stewardship, monitoring of viral genotypes, and consideration of combination therapies to reduce selective pressure and prevent the development of resistant viral populations. [19]

Pharmacokinetics of Maribavir:

Absorption:

Maribavir demonstrates favorable absorption characteristics following oral administration, making it suitable for outpatient therapy. Theoretically, it exhibits high oral bioavailability, generally exceeding 90%, which indicates efficient uptake from the gastrointestinal tract into systemic circulation. Peak plasma concentrations are typically achieved within 1 to 3 hours after dosing, reflecting rapid absorption kinetics. The presence of food has minimal clinically significant impact on its absorption, allowing flexibility in administration with or without meals. This predictable absorption profile contributes to consistent therapeutic drug levels and enhances patient compliance compared to intravenously administered antivirals. [20]

Distribution:

Following absorption, maribavir is widely distributed in the systemic circulation, with a relatively moderate volume of distribution. It exhibits a high degree of plasma protein binding, approximately 98%, primarily to albumin and other plasma proteins. Theoretically, this high protein binding influences its pharmacologically active free fraction, although sufficient unbound drug remains available to exert antiviral effects. Maribavir demonstrates adequate tissue penetration, enabling it to reach sites of CMV infection, particularly in transplant recipients. However, its distribution is largely confined to extracellular compartments, and its penetration into certain sanctuary sites, such as the central nervous system, may be limited. [20]

Metabolism:

Maribavir undergoes extensive hepatic metabolism, primarily mediated by cytochrome P450 enzymes, particularly CYP3A4. Theoretically, this metabolic pathway transforms maribavir into inactive metabolites, which do not contribute significantly to antiviral activity. The reliance on hepatic metabolism suggests that liver function plays an important role in drug clearance, although clinical studies indicate that mild to moderate hepatic impairment does not substantially alter its pharmacokinetics. The metabolic profile also introduces the potential for drug–drug interactions with other agents that induce or inhibit CYP3A4 activity. [20]

Elimination:

Elimination of maribavir occurs through both renal and fecal pathways, reflecting a dual excretion mechanism. The terminal elimination half-life supports a twice-daily dosing regimen, maintaining adequate plasma concentrations for sustained antiviral activity. A portion of the drug is excreted unchanged, while the remainder is eliminated as metabolites. Theoretically, renal clearance plays a secondary role compared to hepatic metabolism, which explains why significant accumulation is not typically observed in patients with renal impairment. This balanced elimination profile contributes to the drug's overall safety and tolerability. [20]

Special Populations:

Pharmacokinetic studies indicate that maribavir maintains a relatively stable profile across various patient populations. In individuals with renal impairment, no significant dose adjustments are generally

required, as renal excretion is not the primary elimination pathway. Similarly, patients with mild to moderate hepatic impairment do not exhibit clinically meaningful changes in drug exposure, suggesting a degree of metabolic resilience. Age-related variations, including those in elderly patients, do not significantly affect pharmacokinetics, allowing standard dosing across adult populations. However, data in pediatric populations remain limited, and further studies are required to establish dosing guidelines in this group. [20]

Drug–Drug Interactions:

Maribavir has a notable potential for drug–drug interactions, primarily due to its involvement with CYP3A4-mediated metabolism. Theoretically, co-administration with strong CYP3A4 inducers, such as rifampin, may reduce maribavir plasma concentrations and compromise antiviral efficacy. Conversely, CYP3A4 inhibitors may increase drug exposure, potentially enhancing both efficacy and the risk of adverse effects. Additionally, maribavir can influence the pharmacokinetics of other medications, particularly immunosuppressive agents such as tacrolimus and cyclosporine, which are commonly used in transplant recipients. These interactions may lead to elevated levels of co-administered drugs, necessitating careful therapeutic drug monitoring and dose adjustments. Importantly, maribavir should not be co-administered with certain antivirals like ganciclovir or valganciclovir, as antagonistic interactions have been observed. Overall, understanding and managing these interactions is critical for optimizing therapeutic outcomes and minimizing adverse effects in complex clinical settings. [20]

Transition to Clinical Application:

The transition of Maribavir from experimental development to clinical application represents a critical phase in its therapeutic evolution, driven by the need to address unmet clinical challenges in cytomegalovirus (CMV) management. Following promising preclinical findings and favorable pharmacokinetic and pharmacodynamic profiles in early human studies, maribavir advanced into clinical trials with a focus on safety, tolerability, and antiviral efficacy in high-risk patient populations. Initial Phase I trials in healthy volunteers confirmed its oral bioavailability, predictable pharmacokinetics, and acceptable safety profile, establishing a foundation for further clinical investigation. Subsequent Phase II studies expanded its evaluation to transplant recipients, demonstrating significant reductions in CMV viral load and acceptable tolerability across a range of dosing regimens. These findings supported the theoretical advantage of targeting the UL97 kinase, particularly in patients who exhibited resistance or intolerance to conventional therapies.

However, early attempts to utilize maribavir as a prophylactic agent in transplant settings yielded inconsistent outcomes, with insufficient efficacy in preventing CMV reactivation. This limitation prompted a strategic reorientation of clinical development toward its use in the treatment of refractory and resistant CMV infections, where existing therapeutic options were inadequate. This shift proved pivotal, as later-stage clinical trials demonstrated that maribavir was highly effective in achieving viral clearance in patients who had failed standard antiviral therapies. Its oral administration further

facilitated its integration into clinical practice by enabling outpatient management and reducing the need for hospitalization associated with intravenous treatments.

The successful completion of Phase III trials ultimately led to regulatory approval of maribavir for the treatment of refractory CMV infection in transplant recipients. In clinical settings, its use is particularly valuable in patients with drug-resistant CMV strains or those experiencing significant toxicity from conventional antivirals. [21]

Clinical Development and Trial Evidence:

Phase I Clinical Trials:

The early clinical development of Maribavir began with Phase I trials designed to evaluate its safety, tolerability, and pharmacokinetic profile in healthy human subjects. These studies established that maribavir is well tolerated across a wide range of doses, with no dose-limiting toxicities observed. The pharmacokinetic data demonstrated rapid absorption, high oral bioavailability, and predictable plasma concentration profiles, supporting its suitability for oral administration. Importantly, Phase I trials confirmed the absence of significant hematologic or renal toxicity, which had been major limitations of earlier antivirals such as Ganciclovir and Foscarnet. These findings validated the theoretical expectation that selective UL97 inhibition would minimize off-target effects and provided the basis for advancing maribavir into patient populations. [22]

Phase II Clinical Trials:

Phase II trials represented the first evaluation of maribavir in patients at risk of or actively infected with cytomegalovirus (CMV), particularly hematopoietic stem cell transplant (HSCT) recipients. These studies primarily focused on determining optimal dosing regimens and assessing antiviral efficacy. Multiple dosing strategies, typically ranging from 400 mg to 1200 mg administered twice daily, were investigated.

The results demonstrated:

- CMV DNA clearance rates ranging from 60% to 80%
- Rapid decline in viral load within the first few weeks of therapy
- Favorable tolerability profile across dose groups

A key observation was that increasing the dose beyond a certain threshold did not significantly enhance efficacy, suggesting a plateau in pharmacodynamic response. This finding informed dose optimization strategies for later trials. Additionally, maribavir showed activity against CMV strains resistant to DNA polymerase inhibitors, reinforcing its clinical value in refractory infections.

However, Phase II trials evaluating maribavir for prophylaxis in transplant recipients yielded less promising results. The inability to significantly reduce CMV reactivation rates in this setting highlighted limitations in its preventive application and influenced subsequent clinical development strategies. [22]

Phase III Clinical Trials (SOLSTICE Trial):

The pivotal Phase III trial, commonly referred to as the SOLSTICE study, marked a defining moment in the clinical development of maribavir. This randomized, open-label, multicenter trial compared

maribavir with investigator-assigned therapy (IAT), which included conventional antivirals such as valganciclovir, foscarnet, or cidofovir.

Key Findings:

- Primary endpoint: CMV viremia clearance at Week 8
- Maribavir demonstrated superior efficacy compared to IAT
- Higher rates of sustained viral clearance
- Lower discontinuation rates due to adverse events

Clinical Significance:

- Provided robust evidence for use in refractory/resistant CMV infections
- Demonstrated improved tolerability compared to standard therapies
- Supported regulatory approval

Notably, maribavir significantly reduced the incidence of treatment-limiting toxicities, particularly:

- Neutropenia (common with ganciclovir)
- Nephrotoxicity (associated with foscarnet and cidofovir) [22]

Table 2: Completed key clinical trials investigating the efficacy and safety of maribavir in the treatment of cytomegalovirus

Trial (ClinicalTrials.gov ID)	**Study Design & Phase**	**Population**	**Treatment Regimen**	**Comparator**	**Primary End Point**	**Key Efficacy Results**	**Safety Results**	**References**
SOLSTICE (NCT01432597)	Randomized, double-blind, Phase II	Refractory/resistant CMV infection; adults (n = 132)	Maribavir 400 mg orally BID	Placebo + investigator-assigned therapy	Proportion with confirmed CMV DNA < LLOQ at Week 8	55.7% (maribavir) vs 23.9% (placebo); $p = 0.002$	Dysgeusia (23%), nausea (15%); low rates of grade 3/4 hematologic or renal AEs (<5%)	Avery RK et al., J Infect Dis. 2020
SOLSTICE Extension (NCT01432597)	Open-label extension	Adults and adolescents ≥12 years who completed SOLSTICE (n = 118)	Maribavir 400 mg orally BID (up to 52 weeks)	None	Maintenance of viral suppression through Week 48	71% maintained CMV DNA < LLOQ at Week 48	Consistent with parent study; low discontinuation (~9%)	Avery RK et al., Clin Infect Dis. 2021
SOLSTICE Adolescent Cohort (NCT01432597)	Post hoc analysis of Phase II	Adolescents 12–<18 years (n = 32)	Maribavir 400 mg orally BID	Placebo + investigator-assigned therapy	Proportion with confirmed CMV DNA < LLOQ at Week 8	53.1% (maribavir) vs 15.4% (placebo)	Safety similar to adults; dysgeusia most common (~19%)	Luchsinger LL et al., Clin Infect Dis. 2022
STRIVE (NCT03143785)	Randomized, open-label, Phase III	Refractory/resistant CMV infection; adults (n = 367)	Maribavir 400 mg orally BID	Investigator-assigned therapy	Proportion with confirmed CMV DNA < LLOQ at Week 8	55% (maribavir) vs 24% (IAT); $p < 0.001$	Lower grade 3/4 AEs (31% vs 55%); less nephrotoxicity and neutropenia	Marty FM et al., N Engl J Med. 2021
Pooled Phase II/III Analysis	Integrated analysis	Adults and adolescents ≥12 years (n = 499)	Maribavir 400 mg orally BID	Placebo or investigator-assigned therapy	Proportion with confirmed CMV DNA < LLOQ at Week 8	Overall response rate ~56.1% with maribavir	Dysgeusia (23%), nausea (14%); low hematologic and renal toxicity	Goldner BN et al., Clin Infect Dis. 2022

Table 3: Summary of key efficacy results from Phase II and III studies evaluating Maribavir for treatment of cytomegalovirus infection

Study (Trial Name / Phase)	**Population**	**Treatment Regimen**	**Comparator**	**Primary Endpoint**	**Key Efficacy Outcome**	**Additional Findings**
Phase II Dose-Finding Studies	HSCT recipients with CMV infection	Maribavir 400–1200 mg BID	Placebo	CMV DNA clearance	~60–80% viral clearance across dose groups	Rapid viral load decline; plateau effect at higher doses
SOLSTICE Phase II (NCT01432597)	Adults with refractory/resistant CMV (n≈132)	Maribavir 400 mg BID	Placebo + investigator-assigned therapy	CMV DNA < LLOQ at Week 8	55.7% vs 23.9% (p = 0.002)	Significant superiority over control
SOLSTICE Adolescent Subgroup	Adolescents (12–<18 years)	Maribavir 400 mg BID	Placebo + investigator therapy	CMV DNA < LLOQ at Week 8	53.1% vs 15.4%	Comparable efficacy to adults
Phase II Prophylaxis Trials	HSCT recipients (prophylaxis setting)	Maribavir (various doses)	Placebo	Prevention of CMV infection	No significant reduction in CMV reactivation	Limited role in prophylaxis
Phase III STRIVE (NCT03143785)	Adults with refractory/resistant CMV (n≈367)	Maribavir 400 mg BID	Investigator-assigned therapy (e.g., Ganciclovir, Foscarnet, Cidofovir)	CMV DNA < LLOQ at Week 8	55% vs 24% (p < 0.001)	Superior efficacy; better tolerability
Phase III Sustained Response Analysis	Same STRIVE population	Maribavir 400 mg BID	Investigator therapy	Sustained viral clearance (post-treatment)	Higher sustained clearance vs comparator	Reduced recurrence during treatment
Pooled Phase II/III Analysis	Adults & adolescents ≥12 years (n≈499)	Maribavir 400 mg BID	Placebo or investigator therapy	CMV DNA < LLOQ at Week 8	~56.1% overall response	Consistent efficacy across subgroups

Table 4: Summary of key efficacy results from Phase II and III studies evaluating Maribavir for treatment of cytomegalovirus infection

Study (Trial Name / Phase)	**Population**	**Treatment Regimen**	**Comparator**	**Common Adverse Events**	**Serious Adverse Events**	**Treatment Discontinuation**	**Key Safety Findings**
Phase II Dose-Finding Studies	HSCT recipients with CMV infection	Maribavir 400–1200 mg BID	Placebo	Dysgeusia, nausea, diarrhea	Low incidence (<5%)	Rare	Well, tolerated; minimal hematologic and renal toxicity
SOLSTICE Phase II (NCT01432597)	Adults with refractory/resistant CMV	Maribavir 400 mg BID	Placebo + investigator therapy	Dysgeusia (~23%), nausea (~15%)	Low rates of neutropenia and renal toxicity	<10%	Favorable safety vs conventional therapy
SOLSTICE Adolescent Subgroup	Adolescents (12–<18 years)	Maribavir 400 mg BID	Placebo + investigator therapy	Dysgeusia (~19%), mild GI effects	Rare serious AEs	Very low	Safety profile comparable to adults
Phase II Prophylaxis Trials	HSCT recipients	Maribavir (various doses)	Placebo	Taste disturbance, mild GI symptoms	Minimal	Low	No significant toxicity despite prolonged use
Phase III STRIVE (NCT03143785)	Adults with refractory/resistant CMV	Maribavir 400 mg BID	Investigator therapy (Ganciclovir, Foscarnet, Cidofovir)	Dysgeusia (~37%), nausea	Lower Grade 3/4 AEs (≈31% vs 55% comparator)	Significantly lower vs comparator	Reduced nephrotoxicity and myelosuppression
Phase III Sustained Safety Analysis	Same STRIVE population	Maribavir 400 mg BID	Investigator therapy	Persistent dysgeusia	No increase in cumulative toxicity	Low	Safe for extended use
Pooled Phase II/III Analysis	Adults & adolescents ≥12 years	Maribavir 400 mg BID	Placebo or investigator therapy	Dysgeusia (~23%), nausea (~14%), diarrhea	Low hematologic and renal AEs	Low overall	Consistent safety across studies

Real-world evidence:

Real-world evidence for Maribavir confirms its effectiveness and safety in routine clinical practice, particularly in transplant patients with refractory or resistant cytomegalovirus (CMV) infection. Observational studies show viral clearance rates similar to clinical trials, with many patients achieving significant reduction in CMV viral load within 6–8 weeks, even after failure of prior therapies.

Compared to conventional antivirals such as Ganciclovir and Foscarnet, maribavir demonstrates better tolerability, with minimal hematologic and renal toxicity, leading to lower treatment discontinuation rates. Its oral formulation allows outpatient management, improving patient adherence and reducing hospitalization.

However, real-world data also highlight challenges, including CMV recurrence after treatment and the potential emergence of UL97 resistance mutations. Drug–drug interactions, especially with immunosuppressants, require careful monitoring. Overall, maribavir is a valuable and practical option in real-world settings, though individualized management remains essential. [23]

Clinical Efficacy:

The clinical efficacy of Maribavir has been well established, particularly in the treatment of refractory and resistant cytomegalovirus (CMV) infections among transplant recipients. Clinical trials and real-world studies consistently demonstrate that maribavir achieves high rates of viral clearance, with a significant proportion of patients reaching undetectable CMV DNA levels within 6 to 8 weeks of therapy. Its efficacy is especially notable in patients who have failed conventional treatments such as Ganciclovir, Foscarnet, or Cidofovir, highlighting its role as an effective salvage therapy. The drug induces a rapid decline in viral load, reflecting its potent inhibition of UL97 kinase and its impact on multiple stages of viral replication.

In addition to its antiviral potency, maribavir offers sustained viral suppression during treatment, although recurrence of CMV infection has been observed in a subset of patients after discontinuation, particularly in those with ongoing immunosuppression. Subgroup analyses indicate that its efficacy is consistent across both hematopoietic stem cell transplant and solid organ transplant recipients, though outcomes may vary depending on baseline viral load and prior antiviral exposure. Compared to traditional therapies, maribavir provides a favorable balance between efficacy and safety, with fewer treatment-limiting adverse effects, enabling longer treatment durations and improved patient adherence. Overall, maribavir represents a significant advancement in CMV therapeutics, delivering reliable clinical outcomes in complex and high-risk patient populations. [24]

Resistance Mechanisms:

Resistance to Maribavir primarily arises through mutations in the cytomegalovirus (CMV) UL97 gene, which encodes the viral protein kinase targeted by the drug. At the molecular level, these mutations alter the structural configuration of the UL97 enzyme, particularly within the ATP-binding site or adjacent functional domains, thereby reducing the binding affinity of maribavir and diminishing its inhibitory effect. Unlike resistance to conventional antivirals such as Ganciclovir, which often involves impaired phosphorylation and activation of the drug, maribavir resistance directly impacts the drug–target interaction. This distinction reflects its unique mechanism of action and results in a different resistance profile compared to DNA polymerase inhibitors like Foscarnet.

Clinically, resistance is more likely to develop in patients with prolonged antiviral exposure, high viral loads, or severe immunosuppression, conditions that increase selective pressure on the virus. The emergence of resistant viral strains may lead to reduced therapeutic response or virological relapse during treatment. However, maribavir generally retains activity against CMV strains resistant to DNA polymerase inhibitors, making it an important option in salvage therapy. Conversely, certain UL97 mutations associated with maribavir resistance may influence susceptibility to other antivirals, creating complex cross-resistance or even re-sensitization patterns. These dynamics underscore the importance of regular viral load monitoring and genotypic resistance testing during therapy. Overall, while resistance remains a clinical challenge, understanding its molecular basis allows for more informed treatment strategies, including drug switching, sequencing, or potential combination therapy to maintain antiviral efficacy. [25]

Advanced Safety and Risk–Benefit Analysis:

The advanced safety and risk–benefit profile of Maribavir reflects a significant improvement over traditional cytomegalovirus (CMV) therapies, largely due to its targeted mechanism of action. Unlike conventional antivirals such as Ganciclovir, which is associated with bone marrow suppression, or Foscarnet and Cidofovir, which carry substantial nephrotoxic risks, maribavir demonstrates minimal hematologic and renal toxicity. The most commonly reported adverse effect is dysgeusia (taste disturbance), along with mild gastrointestinal symptoms such as nausea and diarrhea, which are generally well tolerated and rarely lead to treatment discontinuation. This favorable safety profile enables longer treatment durations and uses in high-risk populations, particularly transplant recipients with pre-existing organ dysfunction.

From a risk–benefit perspective, maribavir offers substantial clinical advantages, especially in patients with refractory or resistant CMV infections where alternative treatment options are limited or poorly tolerated. Its oral administration further enhances patient adherence and reduces hospitalization needs associated with intravenous therapies. However, certain risks remain, including the potential for drug–drug interactions, particularly with immunosuppressive agents like tacrolimus and cyclosporine, which may require careful monitoring and dose adjustments.

Additionally, the emergence of resistance mutations and the possibility of viral recurrence after treatment discontinuation must be considered in long-term management strategies. Overall, the benefits of maribavir—namely its efficacy, improved safety, and ease of administration—generally outweigh its risks, making it a valuable therapeutic option in complex CMV treatment scenarios, provided that appropriate monitoring and individualized patient management are implemented. [26]

Clinical Guidelines and Treatment Algorithms:

Current clinical guidelines position Maribavir as a targeted therapeutic option primarily for the management of refractory or resistant cytomegalovirus (CMV) infections, particularly in hematopoietic stem cell and solid organ transplant recipients. In standard treatment algorithms, first-line therapy for CMV infection typically involves DNA polymerase inhibitors such as Ganciclovir or its oral prodrug Valganciclovir, given their established efficacy in initial disease management. However, in cases where patients fail to respond, develop resistance, or experience significant toxicity, a transition to maribavir is recommended due to its distinct mechanism targeting UL97 kinase and its improved safety profile. Clinical decision-making also incorporates virological monitoring, including quantitative CMV PCR to assess treatment response and detect early signs of failure. In more complex cases, particularly those involving resistance mutations, alternative agents such as Foscarnet or Cidofovir may still be considered, although their use is limited by toxicity. Importantly, maribavir is generally not recommended for primary prophylaxis, where agents like Letermovir are preferred. Overall, treatment algorithms emphasize individualized therapy based on patient risk factors, prior drug exposure, resistance profiles, and tolerability, with maribavir playing a central role in second-line and salvage treatment strategies. [27]

Future Directions and Emerging Research:

Combination Therapy:

Future research is increasingly focused on combination strategies involving Maribavir to enhance antiviral efficacy and reduce the risk of resistance development. The theoretical rationale for combination therapy lies in targeting multiple stages of the cytomegalovirus (CMV) life cycle simultaneously, thereby limiting viral escape mechanisms. For example, combining maribavir, which inhibits UL97 kinase, with Letermovir, which targets the viral terminase complex, may provide synergistic effects by disrupting both viral replication and DNA packaging. Additionally, integration with immune-based therapies or adjunct antivirals could further improve outcomes in patients with refractory infection. Although clinical data are still emerging, combination approaches hold promise for improving viral clearance rates and minimizing recurrence. [28]

Expansion to New Populations:

The clinical application of maribavir is expected to expand beyond its current indication in transplant recipients with refractory CMV infection. Ongoing research is evaluating its safety and efficacy in broader patient populations, including pediatric patients, individuals with congenital CMV infection, and non-transplant immunocompromised individuals such as those receiving chemotherapy or biologic therapies. The favorable safety profile of maribavir makes it a strong candidate for use in these vulnerable groups, where traditional antivirals may be poorly tolerated. Expanding its use will require careful dose optimization, pharmacokinetic studies, and long-term outcome data to ensure safety across diverse populations. [29]

Long-Term Safety Studies:

While short- and medium-term safety data for maribavir are well established, long-term safety remains an important area of investigation. Extended use in transplant recipients raises questions regarding cumulative toxicity, potential metabolic effects, and the long-term impact on organ function. Additionally, prolonged antiviral exposure may influence the development of resistance mutations, necessitating ongoing surveillance. Future longitudinal studies and post-marketing data will be essential to assess the durability of efficacy, the incidence of late adverse effects, and the overall safety of chronic or repeated treatment courses with maribavir. [30]

Novel Drug Development Inspired by Maribavir:

The success of maribavir has provided a strong proof-of-concept for targeting viral kinases as an antiviral strategy, encouraging the development of next-generation agents with similar or improved mechanisms. By demonstrating that selective inhibition of the UL97 kinase can effectively control CMV replication with minimal toxicity, maribavir has shifted the paradigm of antiviral drug design toward highly specific molecular targets. This has stimulated interest in identifying additional viral enzymes and regulatory proteins as therapeutic targets, as well as designing compounds with enhanced potency, resistance profiles, and pharmacokinetic properties. Such innovations may lead to a new class of antivirals that extend beyond CMV to other herpesviruses and viral pathogens. [31]

Integration with Immunotherapy:

An emerging area of research involves combining maribavir with immunotherapeutic approaches to achieve more comprehensive control of CMV infection. Since CMV pathogenesis is closely linked to host immune status, strategies such as adoptive T-cell therapy, CMV-specific immune reconstitution, and therapeutic vaccines may complement antiviral treatment. Maribavir could serve as a bridge therapy to suppress viral replication while immune function is restored, thereby reducing reliance on prolonged antiviral use. This integrated approach has the potential to improve long-term outcomes, reduce recurrence rates, and enhance immune-mediated viral

clearance. As research progresses, the combination of targeted antivirals and immunotherapy may represent the future of CMV management. [32]

Critical Discussion:

The development and clinical integration of Maribavir represent a significant advancement in the management of cytomegalovirus (CMV) infection, particularly in immunocompromised populations. Its novel mechanism of action—targeting the UL97 protein kinase—addresses key limitations associated with conventional antivirals such as Ganciclovir, Foscarnet, and Cidofovir, including hematologic toxicity, nephrotoxicity, and cross-resistance. Clinically, maribavir has demonstrated strong efficacy in refractory and resistant CMV infections, supported by both randomized trials and real-world evidence, and its oral administration significantly enhances patient convenience and adherence. These attributes collectively position maribavir as a transformative option in transplant infectious disease management.

However, a critical evaluation reveals that maribavir is not without limitations. One of the major concerns is the development of resistance mediated by UL97 mutations, which can compromise long-term efficacy, particularly in patients requiring prolonged therapy. Additionally, while maribavir achieves effective viral suppression, it does not eliminate latent CMV reservoirs, leading to a risk of recurrence after treatment discontinuation. This highlights a broader limitation of current antiviral strategies, which primarily target active replication rather than latency. Furthermore, its limited role in prophylaxis, where agents like Letermovir are more effective, restricts its use to treatment rather than prevention.

Another important consideration is the complexity of managing drug–drug interactions, especially in transplant recipients receiving immunosuppressive therapy. Maribavir's interaction with agents such as tacrolimus and cyclosporine necessitates careful therapeutic drug monitoring, adding to the clinical management burden. Additionally, the cost of therapy and accessibility in resource-limited settings may pose barriers to widespread adoption, particularly in regions with high transplant volumes but limited healthcare resources.

From a broader perspective, maribavir exemplifies a shift toward targeted antiviral therapy, emphasizing specificity and safety. However, its optimal use will likely depend on integration into combination regimens, personalized treatment strategies, and improved diagnostic tools for resistance detection. Future research should focus on overcoming current limitations, including resistance development, recurrence, and the inability to target latent infection. In conclusion, while maribavir represents a major step forward in CMV therapeutics, its full potential will be realized only through continued innovation, strategic clinical application, and integration with emerging therapeutic approaches such as immunotherapy and precision medicine.

Conclusion:

In conclusion, Maribavir represents a significant advancement in the treatment of cytomegalovirus (CMV) infection, particularly in immunocompromised patients such as transplant recipients. Across foundational insights into CMV biology and pharmacology, clinical trial evidence, and emerging data on resistance and future applications, maribavir has demonstrated a unique and clinically valuable profile. Its novel mechanism of action targeting the UL97 kinase differentiates it from traditional antivirals such as Ganciclovir and Foscarnet, enabling effective management of refractory and resistant infections while minimizing common toxicities.

Clinical studies and real-world evidence consistently support its efficacy in achieving viral clearance with improved tolerability, making it a preferred option in complex treatment scenarios. However, challenges such as the development of resistance, risk of recurrence, and drug–drug interactions highlight the need for careful patient monitoring and individualized treatment strategies. Furthermore, its limited role in prophylaxis and higher cost may restrict its broader application.

Overall, maribavir marks an important step toward more targeted and safer antiviral therapies. Future research focusing on combination treatments, expanded patient populations, and integration with immunotherapeutic approaches will further define its role in CMV management. With continued investigation and optimized clinical use, maribavir is expected to play a central role in improving outcomes for patients affected by CMV infections.

CONFLICT OF INTEREST-

Nill

ACKNOWLEDGE

The author would like to thank the Samarth Institute of Pharmacy, Belhe,Pune, university library, and all other sources for their help and advice in writing this review.

References:

1. Takeda Pharmaceuticals America Inc. LIVTENCITY US pre scribing information. Accessed May 24, 2023.
2. Takeda Pharmaceuticals International AG Ireland Branch. LIVTENCITY summary of product characteristics (EMA). Accessed May 24, 2023.
3. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitiv ity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124-127.
4. Song I, Sun K, Ilic K, Martin P. Summary of maribavir (SHP620) drug–drug interactions based on accumulated clinical and non clinical data. Biol Blood Marrow Transplant. 2019;25:S370-S371.

5. Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post- transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75:690-701.

6. Griffiths P, Reeves M. Pathogenesis of human cytomegalo virus in the immunocompromised host. Nat Rev Microbiol. 2021;19:759-773.

7. Steingruber M, Marschall M. The cytomegalovirus protein ki nase pUL97: host interactions, regulatory mechanisms and antiviral drug targeting. Microorganisms. 2020;8:515.

8. Takeda Canada Inc. LIVTENCITY product monograph includ ing patient medication information. Accessed May 24, 2023.

9. Takeda Pharmaceuticals Australia Pty Ltd. LIVTENCITY Australia product information. Accessed May 24, 2023.

10. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev. 2008;72:249-265.

11. Shannon- Lowe CD, Emery VC. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cy tomegalovirus UL97 protein. Herpesviridae. 2010;1:4.

12. Prichard MN. Function of human cytomegalovirus UL97 ki nase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19:215-229.

13. Chou S. Approach to drug- resistant cytomegalovirus in trans plant recipients. Curr Opin Infect Dis. 2015;28:293-299.

14. Draganova EB, Thorsen MK, Heldwein EE. Nuclear egress. Curr Issues Mol Biol. 2021;41:125-170.

15. Halpern- Cohen V, Blumberg EA. New perspectives on anti microbial agents: maribavir. Antimicrob Agents Chemother. 2022;66:e0240521.

16. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and se lective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L- riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46:2365-2372.

17. ClinicalTrials.gov. A study of maribavir compared to valganci clovir to treat cytomegalovirus infections in people who have received stem cell transplants. Accessed April, 2023.

18. ClinicalTrials.gov. A study to evaluate the safety and tolerabil ity, pharmacokinetics, and antiviral activity of maribavir for the treatment of children and teenage transplant recipients with CMV infection. https:// clini caltr ials. gov/ ct2/ show/ NCT05 319353. Accessed April, 2023.

19. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263 W94, a novel oral anti- human cytomegalovirus agent, in healthy and human immunodeficiency virus- infected subjects. Antimicrob Agents Chemother. 2003;47:1334-1342.

20. Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic- cell or solid- organ transplant recipients: a ran domized, dose- ranging, double- blind, phase 2 study. Clin Infect Dis. 2019;68:1255-1264.

21. Chou S, Alain S, Cervera C, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resis tant cytomegalovirus infection in transplant recipients. J Infect Dis. 2023:jiad293.

22. Chou S, Ercolani RJ, Derakhchan K. Antiviral activity of marib avir in combination with other drugs active against human cy tomegalovirus. Antivir Res. 2018;157:128-133.

23. Genentech USA, Inc. Valcyte US prescribing information. Accessed May 24, 2023.

24. Song I, Ilic K, Sun K, Martin P. Clinical pharmacology of marib avir (SHP620): a comprehensive overview. Biol Blood Marrow Transplant. 2019;25:S342.

25. Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for pre emptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381:1136-1147.

26. Pescovitz MD, Bloom R, Pirsch J, Johnson J, Gelone S, Villano SA. A randomized, double- blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipi ents. Am J Transplant. 2009;9:2324-2330.

27. Sun K, Hayes S, Farrell C, Song IH. Population pharmacokinetic modeling and simulation of maribavir to support dose selec tion and regulatory approval in adolescents with posttransplant refractory cytomegalovirus. CPT Pharmacometrics Syst Pharmacol. 2023;12:719-723.

28. Halpern- Cohen V, Blumberg EA. New perspectives on anti microbial agents: maribavir. Antimicrob Agents Chemother. 2022;66:e0240521.

29. Song I, Chen G, Hayes S, et al. Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infection. Poster Presented at Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. April 23–26, 2022, Salt Lake City, UT. Transplant Cell Ther. 2022;28: S368-S369.

30. Griffiths P, Reeves M. Pathogenesis of human cytomegalo virus in the immunocompromised host. Nat Rev Microbiol. 2021;19:759-773.

31. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev. 2008;72:249-265.

32. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitiv ity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37:124-127.